Wall Street analysts forecast that Albemarle Co. (NYSE:ALB) will post earnings per share of $1.46 for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for Albemarle’s earnings, with the lowest EPS estimate coming in at $1.42 and the highest estimate coming in at $1.52. Albemarle reported earnings of $1.34 per share during the same quarter last year, which indicates a positive year over year growth rate of 9%. The firm is scheduled to issue its next quarterly earnings report on Tuesday, February 26th.

On average, analysts expect that Albemarle will report full-year earnings of $5.40 per share for the current financial year, with EPS estimates ranging from $5.28 to $5.47. For the next fiscal year, analysts anticipate that the company will report earnings of $6.12 per share, with EPS estimates ranging from $5.58 to $6.74. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Albemarle.

Albemarle (NYSE:ALB) last announced its earnings results on Wednesday, November 7th. The specialty chemicals company reported $1.31 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.25 by $0.06. The company had revenue of $778.00 million for the quarter, compared to analyst estimates of $796.79 million. Albemarle had a return on equity of 15.39% and a net margin of 10.44%. The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the company earned $1.08 earnings per share.

A number of equities analysts have recently weighed in on ALB shares. Berenberg Bank set a $130.00 target price on Albemarle and gave the stock a “buy” rating in a research note on Friday, November 9th. Loop Capital set a $130.00 price target on Albemarle and gave the stock a “buy” rating in a research report on Friday, October 19th. SunTrust Banks raised Albemarle from a “hold” rating to a “buy” rating and increased their price target for the stock from $110.00 to $115.00 in a research report on Tuesday, September 4th. Zacks Investment Research raised Albemarle from a “hold” rating to a “buy” rating and set a $104.00 price target on the stock in a research report on Tuesday, August 7th. Finally, ValuEngine raised Albemarle from a “sell” rating to a “hold” rating in a report on Friday, September 21st. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and eighteen have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $122.63.

Shares of NYSE ALB opened at $102.70 on Friday. The company has a market cap of $10.54 billion, a PE ratio of 22.37, a PEG ratio of 1.29 and a beta of 1.53. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.18 and a current ratio of 1.83. Albemarle has a 1-year low of $86.75 and a 1-year high of $138.67.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 2nd. Investors of record on Friday, December 14th will be issued a dividend of $0.335 per share. This represents a $1.34 annualized dividend and a dividend yield of 1.30%. The ex-dividend date is Thursday, December 13th. Albemarle’s dividend payout ratio (DPR) is 29.19%.

In related news, EVP Karen G. Narwold sold 3,100 shares of the firm’s stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $97.11, for a total transaction of $301,041.00. Following the sale, the executive vice president now owns 30,242 shares of the company’s stock, valued at approximately $2,936,800.62. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.80% of the company’s stock.

A number of large investors have recently made changes to their positions in the stock. Macquarie Group Ltd. raised its position in Albemarle by 29.8% during the 3rd quarter. Macquarie Group Ltd. now owns 53,282 shares of the specialty chemicals company’s stock worth $5,317,000 after purchasing an additional 12,225 shares during the last quarter. Brown Brothers Harriman & Co. raised its position in Albemarle by 4.8% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 25,300 shares of the specialty chemicals company’s stock worth $2,524,000 after purchasing an additional 1,150 shares during the last quarter. Vectors Research Management LLC bought a new position in Albemarle during the 3rd quarter worth $648,000. Point72 Hong Kong Ltd raised its position in Albemarle by 1,791.2% during the 3rd quarter. Point72 Hong Kong Ltd now owns 2,572 shares of the specialty chemicals company’s stock worth $257,000 after purchasing an additional 2,436 shares during the last quarter. Finally, Covington Capital Management raised its position in Albemarle by 9.1% during the 3rd quarter. Covington Capital Management now owns 6,298 shares of the specialty chemicals company’s stock worth $628,000 after purchasing an additional 525 shares during the last quarter. 91.60% of the stock is owned by institutional investors and hedge funds.

About Albemarle

Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. Its Lithium and Advanced Materials segment offers lithium compounds, including lithium carbonate, lithium hydroxide, lithium chloride, and lithium specialties, as well as reagents, such as butyllithium and lithium aluminum hydride for applications in lithium batteries for consumer electronics and automobiles, high performance greases, thermoplastic elastomers for car tires, rubber soles, plastic bottles, catalysts for chemical reactions, organic synthesis processes, life science, pharmaceutical, and other markets.

Read More: Quiet Period

Get a free copy of the Zacks research report on Albemarle (ALB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Albemarle (NYSE:ALB)

Receive News & Ratings for Albemarle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle and related companies with MarketBeat.com's FREE daily email newsletter.